Tudor Investment Corp Et Al Acquires Shares of 17,053 Allogene Therapeutics, Inc. (NASDAQ:ALLO)

Tudor Investment Corp Et Al acquired a new stake in Allogene Therapeutics, Inc. (NASDAQ:ALLO – Get Rating) during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 17,053 shares of the company’s stock, valued at approximately $184,000.

Several other hedge funds also recently bought and sold shares of the business. Point72 Asset Management L.P. bought a new position in Allogene Therapeutics in the 3rd quarter valued at $3,167,000. Cubist Systematic Strategies LLC grew its position in Allogene Therapeutics by 110.8% in the 3rd quarter. Cubist Systematic Strategies LLC now owns 579,245 shares of the company’s stock valued at $6,256,000 after acquiring an additional 304,445 shares during the last quarter. Moore Capital Management LP bought a new position in shares of Allogene Therapeutics during the 3rd quarter worth $1,296,000. Penserra Capital Management LLC grew its position in shares of Allogene Therapeutics by 211.8% during the 3rd quarter. Penserra Capital Management LLC now owns 17,272 shares of the company’s stock worth $186,000 after buying an additional 11,732 shares in the last quarter. Finally, MetLife Investment Management LLC grew its position in shares of Allogene Therapeutics by 4.1% during the 3rd quarter. MetLife Investment Management LLC now owns 42,018 shares of the company’s stock worth $454,000 after buying an additional 1,668 shares in the last quarter. Institutional investors own 72.94% of the company’s stock.

Wall Street Analyst Weigh In

ALLO has been the topic of a number of recent research reports. Bank of America downgraded Allogene Therapeutics from a “buy” rating to an “underperform” rating and dropped their price target for the stock from $24.00 to $9.00 in a research report on Monday, December 12th. Oppenheimer dropped their price target on Allogene Therapeutics from $32.00 to $28.00 and set an “outperform” rating on the stock in a research report on Wednesday, March 1st. The Goldman Sachs Group dropped their price target on Allogene Therapeutics from $35.00 to $31.00 and set a “buy” rating on the stock in a research report on Wednesday, March 1st. HC Wainwright dropped their price target on Allogene Therapeutics from $43.00 to $29.00 and set a “buy” rating on the stock in a research report on Monday, November 21st. Finally, EF Hutton Acquisition Co. I restated a “buy” rating and set a $15.00 price objective on shares of Allogene Therapeutics in a research note on Wednesday, March 1st. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $18.67.

Insider Transactions at Allogene Therapeutics

In other news, General Counsel Veer Bhavnagri sold 5,602 shares of the firm’s stock in a transaction dated Thursday, December 15th. The stock was sold at an average price of $7.53, for a total value of $42,183.06. Following the completion of the transaction, the general counsel now directly owns 583,677 shares in the company, valued at $4,395,087.81. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders sold a total of 11,602 shares of company stock worth $83,853 over the last three months. 29.80% of the stock is currently owned by insiders.

Allogene Therapeutics Stock Performance

Allogene Therapeutics stock opened at $5.70 on Friday. The stock has a 50-day moving average of $6.79 and a two-hundred day moving average of $9.21. Allogene Therapeutics, Inc. has a one year low of $5.41 and a one year high of $17.49. The stock has a market cap of $823.65 million, a PE ratio of -2.46 and a beta of 0.81.

Allogene Therapeutics (NASDAQ:ALLO – Get Rating) last announced its quarterly earnings data on Tuesday, February 28th. The company reported ($0.66) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.71) by $0.05. Allogene Therapeutics had a negative return on equity of 43.44% and a negative net margin of 136,885.59%. The firm had revenue of $0.05 million during the quarter, compared to analysts’ expectations of $0.06 million. During the same period last year, the business posted ($0.54) earnings per share. The company’s revenue for the quarter was down 6.0% compared to the same quarter last year. As a group, sell-side analysts predict that Allogene Therapeutics, Inc. will post -2.57 EPS for the current fiscal year.

About Allogene Therapeutics

(Get Rating)

Allogene Therapeutics, Inc operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells.